RESULTS OF THE FIRST RANDOMIZED PHASE II STUDY OF CATIONIC LIPOSOMAL PACLITAXEL (ENDOTAG™-1) TARGETING TUMOR ENDOTHELIAL CELLS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER (TNBC)

被引：0
|
作者：
Awada, A. [1 ]
Bondarenko, I. N. [2 ]
Tarasova, O. [3 ]
Bonneterre, J. [4 ]
Nowara, E. [5 ]
Ferrero, J. M. [6 ]
Bakshi, A. V. [7 ]
Glasschroeder, B. [8 ]
Elsasser, U. [8 ]
Piccart, M. [1 ]
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
[2] Dnepropetrovsk State Med Acad, Dnepropetrovsk, Ukraine
[3] Ukraine Acad Med Sci, Inst Med Radiol, Kharkov, Ukraine
[4] Ctr Oscar Lambret, F-59020 Lille, France
[5] Inst M Sklodowskiej Curie, Ctr Onkol, Gliwice, Poland
[6] Ctr Antoine Lacassagne, F-06054 Nice, France
[7] Kaushalya Med Fdn, Thana, India
[8] MediGene AG, Planegg Martinsried, Germany
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [1] Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG"-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC).
    Awada, A.
    Bondarenko, I. N.
    Trasova, O.
    Bonneterre, J.
    Nowara, E.
    Ferrero, J. M.
    Bakshi, A. V.
    Weidenthaler, H.
    Wilke, C.
    Piccart, M. J.
    CANCER RESEARCH, 2011, 71
  • [2] A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
    Awada, A.
    Bondarenko, I. N.
    Bonneterre, J.
    Nowara, E.
    Ferrero, J. M.
    Bakshi, A. V.
    Wilke, C.
    Piccart, M.
    ANNALS OF ONCOLOGY, 2014, 25 (04) : 824 - 831
  • [3] A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).
    Tolaney, Sara M.
    Ziehr, David R.
    Guo, Hao
    Barry, William Thomas
    Higgins, Michaela Jane
    Isakoff, Steven J.
    Brock, Jane E.
    Ivanova, Elena
    Paweletz, Cloud
    Demeo, Michelle
    Ramaiya, Nikhil H.
    Overmoyer, Beth
    Jain, Rakesh K.
    Duda, Dan G.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)
    Parton, Marina
    Bardia, Aditya
    Kummel, Sherko
    Estevez, Laura G.
    Huang, Chiun-Sheng
    Castan, Javier Cortes
    Borrego, Manuel Ruiz
    Telli, Melinda L.
    Lluch, Ana
    Lopez, Rafael
    Beck, J. Thaddeus
    Ismail-Khan, Roohi
    Chen, Shin-Cheh
    Hurvitz, Sara A.
    Mayer, Ingrid A.
    Atienza, Rolando S.
    Cameron, Scott
    Krygowski, Mizue
    Kim, Sung-Bae
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Saha, Poornima
    Rampurwala, Murtuza M.
    Kamaraju, Sailaja
    Hahn, Olwen Mary
    Howard, Frederick Matthew
    Fleming, Gini F.
    Matossian, Margarite
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne D.
    Nanda, Rita
    Stringer-Reasor, Erica Michelle
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Matossian, Margarite
    Saha, Poornima
    Rampurwala, Murtuza
    Kamaraju, Salaija
    Hahn, Olwen
    Howard, Frederick M.
    Fleming, Gini F.
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne
    Nanda, Rita
    Stringer-Reasor, Erica M.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 111 - 119
  • [7] A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)
    Mayer, I. A.
    Jovanovic, B.
    Abramson, V. G.
    Mayer, E. L.
    Sanders, M. E.
    Bardia, A.
    Dillon, P. M.
    Kuba, M. G.
    Carpenter, J. T.
    Chang, J. C.
    Lehmann, B. D.
    Meszoely, I. M.
    Grau, A.
    Shyr, Y.
    Arteaga, C. L.
    Chen, X.
    Pietenpol, J. A.
    CANCER RESEARCH, 2013, 73
  • [8] SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC)
    Llombart, Antonio
    Lluch, Ana
    Villanueva, Cristian
    Delaloge, Suzette
    Morales, Serafin
    Balmana, Judith
    Amillano, Kepa
    Bonnefoi, Herve R.
    Casas, Ana Maria
    Manso, Luis
    Hubert Roche, Henri
    Gonzalez-Santiago, Santiago
    Gavila, Joaquin
    Sanchez-Rovira, Pedro
    Di Cosimo, Serena
    Charpentier, Eric
    Garcia-Ribas, Ignacio
    Penault-Llorca, Frederique Madeleine
    Aura, Claudia
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Dual targeting of αv and α5β1 integrins in triple-negative breast cancer (TNBC)
    Song, Fei
    Do, Kevin
    Fein, Daniel E. C.
    Jahanseir, Narges
    Joshi, Raghav
    Mathew, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).
    Sharma, Priyanka
    Stecklein, Shane Richard
    Yoder, Rachel
    Staley, Joshua M.
    Schwensen, Kelsey
    O'Dea, Anne
    Nye, Lauren Elizabeth
    Elia, Manana
    Satelli, Deepti
    Crane, Gregory
    Madan, Rashna
    O'Neil, Maura F.
    Wagner, Jamie L.
    Larson, Kelsey E.
    Balanoff, Christa
    Phadnis, Milind A.
    Godwin, Andrew K.
    Salgado, Roberto
    Khan, Qamar J.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345